348 related articles for article (PubMed ID: 16797971)
1. Myeloma bone disease and treatment options.
Yeh HS; Berenson JR
Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
[TBL] [Abstract][Full Text] [Related]
2. Treatment for myeloma bone disease.
Yeh HS; Berenson JR
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
[TBL] [Abstract][Full Text] [Related]
3. Myeloma bone disease.
Berenson JR
Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options in the management of myeloma bone disease.
Berenson JR
Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
8. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
9. Advances in the biology and treatment of bone disease in multiple myeloma.
Raje N; Roodman GD
Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
[TBL] [Abstract][Full Text] [Related]
10. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
12. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
13. [Management of multiple myeloma-related bone disease].
Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
[TBL] [Abstract][Full Text] [Related]
14. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
15. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
17. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
19. Local effects of malignancy on bone.
Brown SA; Clines GA; Guise TA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
[TBL] [Abstract][Full Text] [Related]
20. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
